Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.

      Neurology

      Humans, Acetates, administration & dosage, adverse effects, therapeutic use, Adult, Aged, Amines, Cross-Over Studies, Cyclohexanecarboxylic Acids, Double-Blind Method, Excitatory Amino Acid Antagonists, Female, Male, Middle Aged, Pain, etiology, prevention & control, Pain Measurement, Polysomnography, Random Allocation, Research Design, Restless Legs Syndrome, complications, drug therapy, Sample Size, Sleep, drug effects, Treatment Outcome, gamma-Aminobutyric Acid

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS). Patients with RLS (22 idiopathic, 2 secondary to iron deficiency) were randomized and treated for 6 weeks with either gabapentin or placebo. After a 1-week washout they crossed over to the alternative treatment for 6 weeks. Patients were rated at baseline and at scheduled intervals by the RLS Rating Scale, Clinical Global Impression, pain analogue scale, and Pittsburgh Sleep Quality Index. At the end of each treatment period, all-night polysomnography was performed. Compared to placebo, gabapentin was associated with reduced symptoms on all rating scales. In addition, sleep studies showed a significantly reduced periodic leg movements during sleep (PLMS) index and improved sleep architecture (increased total sleep time, sleep efficiency, and slow wave sleep, and decreased stage 1 sleep). Patients whose symptoms included pain benefited most from gabapentin. The mean effective dosage at the end of the 6-week treatment period was 1,855 mg, although therapeutic effects were already observed at the end of week 4 (1,391 mg). Gabapentin improves sensory and motor symptoms in RLS and also improves sleep architecture and PLMS.

          Related collections

          Author and article information

          Journal
          12451200

          Comments

          Comment on this article